Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CP-101,606 in Parkinson's Disease
NCT00163085Phase 2Completed
- Sponsor
- Pfizer
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in levodopa-induced dyskinesia (LID) comparing CP-101,606 Sequence with Placebo Sequence (2 arms). Primary endpoint: Dyskinesia Rating Scale. Started May 2005; status: completed.
02
Drugs
traxoprodil
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT00163085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00163085.